Suppr超能文献

葡萄膜炎性黄斑水肿的视网膜前膜:对视力的影响及对治疗的反应。

Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy.

机构信息

Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Biostatistics, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Am J Ophthalmol. 2014 May;157(5):1048-55. doi: 10.1016/j.ajo.2014.01.020. Epub 2014 Jan 30.

Abstract

PURPOSE

To evaluate the effects of epiretinal membranes on the response of uveitic macular edema to therapy and on visual acuity outcomes.

DESIGN

Retrospective case series.

METHODS

One hundred four eyes of 77 patients with uveitic macular edema were identified at a tertiary care center. Epiretinal membranes were diagnosed when identified by 2 investigators' grading of spectral-domain optical coherence tomography and scored for the presence or absence of surface wrinkling. Outcomes included best-corrected visual acuity, central subfield thickness, and rates of macular edema improvement (>20% reduction in central subfield thickness) and resolution (reduction of central subfield thickness to <315 μm) at 3 and 6 months follow-up.

RESULTS

Seventy-two eyes of 59 patients had an epiretinal membrane on presentation. Eyes without epiretinal membranes and with epiretinal membranes without surface wrinkling were not significantly different at presentation or at 3 and 6 months follow-up. Conversely, eyes with an epiretinal membrane with retinal surface wrinkling had a greater proportion of eyes with 20/200 or worse visual acuity at presentation, and had worse mean acuities at 3 months (20/94 vs 20/35 for eyes without an epiretinal membrane, P = .002) and at 6 months follow-up (20/110 vs 20/36 for eyes without an epiretinal membrane, P = .02). At 6 months of follow-up the mean central subfield thicknesses were: eyes without an epiretinal membrane, 338 ± 23 μm; and eyes with an epiretinal membrane and surface wrinkling, 405 ± 22 μm (P = .05).

CONCLUSIONS

In eyes with epiretinal membranes and retinal surface wrinkling, uveitic macular edema had a poorer visual acuity response to medical therapy and thicker maculae at 6 months.

摘要

目的

评估视网膜前膜对葡萄膜炎性黄斑水肿治疗反应和视力结果的影响。

设计

回顾性病例系列。

方法

在一家三级保健中心,确定了 77 例葡萄膜炎性黄斑水肿患者的 104 只眼。当 2 位研究者根据频域光相干断层扫描分级发现视网膜前膜并对其表面褶皱的存在或不存在进行评分时,诊断为视网膜前膜。结果包括最佳矫正视力、中央子区厚度以及黄斑水肿改善(中央子区厚度减少 20%以上)和缓解(中央子区厚度减少至<315 μm)的比例,随访 3 个月和 6 个月。

结果

59 例患者的 72 只眼在就诊时存在视网膜前膜。无视网膜前膜和无表面褶皱的视网膜前膜的眼在就诊时以及随访 3 个月和 6 个月时无显著差异。相反,有视网膜表面褶皱的视网膜前膜的眼在就诊时视力更差,20/200 或更差的比例更高,且在 3 个月(无视网膜前膜的眼为 20/94,无视网膜前膜的眼为 20/35,P =.002)和 6 个月(无视网膜前膜的眼为 20/110,无视网膜前膜的眼为 20/36,P =.02)随访时视力更差。6 个月时的平均中央子区厚度为:无视网膜前膜的眼为 338 ± 23 μm;有视网膜前膜和表面褶皱的眼为 405 ± 22 μm(P =.05)。

结论

在有视网膜前膜和视网膜表面褶皱的眼中,葡萄膜炎性黄斑水肿对药物治疗的视力反应更差,6 个月时黄斑更厚。

相似文献

1
Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy.
Am J Ophthalmol. 2014 May;157(5):1048-55. doi: 10.1016/j.ajo.2014.01.020. Epub 2014 Jan 30.
2
Subretinal fluid in uveitic macular edema: effect on vision and response to therapy.
Am J Ophthalmol. 2013 Jan;155(1):143-9. doi: 10.1016/j.ajo.2012.06.028. Epub 2012 Sep 27.
3
Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.
Ophthalmology. 2021 May;128(5):719-728. doi: 10.1016/j.ophtha.2020.08.035. Epub 2020 Sep 10.
4
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7.
6
Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.
Eur J Ophthalmol. 2009 Jul-Aug;19(4):622-9. doi: 10.1177/112067210901900417.
7
Comparison of retinal thickness and fundus-related microperimetry with visual acuity in uveitic macular oedema.
Acta Ophthalmol. 2011 Sep;89(6):533-7. doi: 10.1111/j.1755-3768.2009.01750.x. Epub 2009 Dec 9.
8
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.
Am J Ophthalmol. 2011 Dec;152(6):1044-1052.e5. doi: 10.1016/j.ajo.2011.05.028. Epub 2011 Sep 8.
10
Fundus autofluorescence and spectral domain optical coherence tomography in uveitic macular edema.
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1685-9. doi: 10.1007/s00417-009-1149-8. Epub 2009 Aug 11.

引用本文的文献

1
Epiretinal membranes in patients with uveitis: an update on the current state of management.
Int Ophthalmol. 2024 Jun 28;44(1):291. doi: 10.1007/s10792-024-03199-2.
2
Functional and Anatomical Outcomes of Pars Plana Vitrectomy for Epiretinal Membrane in Patients with Uveitis.
Diagnostics (Basel). 2022 Dec 5;12(12):3044. doi: 10.3390/diagnostics12123044.
4
Spectral domain optical coherence tomography findings of patients with pars planitis and risk factors affecting visual acuity.
Int Ophthalmol. 2021 May;41(5):1753-1761. doi: 10.1007/s10792-021-01734-z. Epub 2021 Feb 9.
5
Advances and potential new developments in imaging techniques for posterior uveitis. Part 1: noninvasive imaging methods.
Eye (Lond). 2021 Jan;35(1):33-51. doi: 10.1038/s41433-020-1063-1. Epub 2020 Jul 16.
7
RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE.
Retina. 2019 May;39(5):948-955. doi: 10.1097/IAE.0000000000002044.
8
Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis.
Eye (Lond). 2016 Nov;30(11):1415-1423. doi: 10.1038/eye.2016.133. Epub 2016 Jul 8.
9
Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis.
Indian J Ophthalmol. 2015 Oct;63(10):767-70. doi: 10.4103/0301-4738.171505.
10
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7.

本文引用的文献

1
The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole.
Ophthalmology. 2013 Dec;120(12):2611-2619. doi: 10.1016/j.ophtha.2013.07.042. Epub 2013 Sep 17.
2
Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
Retina. 2013 Nov-Dec;33(10):2003-11. doi: 10.1097/IAE.0b013e3182993ef8.
4
25-gauge Vitrectomy for complicated chronic endogenous/autoimmune uveitis: predictors of outcomes.
Ocul Immunol Inflamm. 2013 Apr;21(2):93-101. doi: 10.3109/09273948.2012.734536. Epub 2013 Jan 2.
6
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.
Am J Ophthalmol. 2011 Dec;152(6):1044-1052.e5. doi: 10.1016/j.ajo.2011.05.028. Epub 2011 Sep 8.
7
The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.
Am J Ophthalmol. 2010 Apr;149(4):550-561.e10. doi: 10.1016/j.ajo.2009.11.019. Epub 2010 Jan 25.
8
Spectral-domain optical coherence tomography for monitoring epiretinal membrane surgery.
Ophthalmology. 2010 Apr;117(4):798-805. doi: 10.1016/j.ophtha.2009.08.034. Epub 2010 Jan 4.
9
Fundus autofluorescence and spectral domain optical coherence tomography in uveitic macular edema.
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1685-9. doi: 10.1007/s00417-009-1149-8. Epub 2009 Aug 11.
10
Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).
Am J Ophthalmol. 2009 Aug;148(2):266-71. doi: 10.1016/j.ajo.2009.03.006. Epub 2009 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验